1. VIP is only drug known that corrects the final stage of molecular hypometabolism: suppression of ribosomal gene and nuclear encoded mitochondrial gene activation (1).
2. VIP is only drug
known that that corrects grey matter nuclear atrophy (looking at hippocampus,
amygdala, caudate, putamen, pallidum and thalamus) (2)
3. VIP is only drug known that corrects coagulation gene upregulation
4. VIP is only drug known that corrects upregulation of TUBB1 and TUBA4A
5. VIP is only drug known that corrects persistent low Ikaros and VIPR1 (3)
6. VIP is only drug that corrects the persistent refractory abnormalities in proteomics of Chronic Inflammatory Response Syndrome (CIRS) (4)
7. VIP corrects elevated pulmonary artery pressure both at rest and acquired (4)
8. VIP corrects low levels of both acquired and thymus derived T regulatory cells
9. VIP continues to be incredibly safe when used according to published criteria (2)
10. VIP corrects dilated cardiomyopathy (ejection fraction and LVIDD) anecdotally with such correction correlated with salutary changes in multiple genes (SLC8B1, ADCY and ADRB1 (adrenoceptor), to name a few) in white blood cells (3)
1. Ryan J, Shoemaker R. RNA-Seq on patients with chronic inflammatory response syndrome (CIRS) treated with vasoactive intestinal polypeptide (VIP) shows a shift in metabolic state and innate immune functions that coincide with healing. Med Res Arch 2016; 4(7): 1-11.
2. Shoemaker R, Katz D, McMahon S, Ryan J. Intranasal VIP safely restores atrophic grey matter nuclei in patients with CIRS. Internal Medicine Review 2017; 3(4): 1-14.
3. Shoemaker R, Ryan J. eBook. 3/1/2018. A Gene Primer for Health Care Providers: The Genomics of CIRS and Associated Molecular Pathways: Interpreting the Transcriptomics Results
4. Shoemaker R, House D, Ryan J. Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings. Health 2013; 5(3): 396-401.